Bluebird Bio Q2 2024 Earnings Conference Call Summary
Financial Highlights
- Q2 2024 net revenue: $161 million
- Cash runway into Q2 2025 based on current financial outlook
Conference Call Details
Bluebird bio held a conference call on August 14, 2024 to discuss its Q2 2024 financial results. The call was hosted by Chief Executive Officer Andrew Obenshain and Chief Financial Officer Kevin Brennan.
Earnings Summary
Bluebird bio reported strong financial results for Q2 2024. Revenue was $161 million, a 20% increase compared to Q2 2023. This growth was driven by increased sales of ZYNTEGLO and SKYSORA.
ZYNTEGLO
ZYNTEGLO, Bluebird bio's gene therapy for beta-thalassemia, continues to perform well commercially. Sales of ZYNTEGLO were $105 million in Q2 2024, a 15% increase compared to Q2 2023.
SKYSORA
SKYSORA, Bluebird bio's gene therapy for cerebral adrenoleukodystrophy (CALD), also saw strong sales growth. Sales of SKYSORA were $56 million in Q2 2024, a 30% increase compared to Q2 2023.
Financial Outlook
Bluebird bio provided an update on its financial outlook for 2024. The company expects revenue to be between $620 million and $650 million for the full year.
Cash Runway
As of June 30, 2024, Bluebird bio had $422 million in cash and cash equivalents. This gives the company a cash runway into Q2 2025 based on its current financial outlook.
Conference Call Transcript
A transcript of the Q2 2024 conference call is available on the Bluebird bio website: https://ir.bluebirdbio.com/
Posting Komentar